WO2012071535A2

WO2012071535A2 - Pediatric formulation

Info

Publication number: WO2012071535A2
Application number: PCT/US2011/062085
Authority: WO
Inventors: Mingda Bi; Fernando Alvarez-Nunez; Francisco Javier Alvarez
Original assignee: Amgen Inc
Current assignee: Amgen Inc
Priority date: 2010-11-23
Filing date: 2011-11-23
Publication date: 2012-05-31
Anticipated expiration: 2013-05-23
Also published as: CA2818565A1; US20190216737A1; HRP20200691T1; WO2012071535A3; ES2793724T3; US20180098940A1; SMT202000314T1; EP2642980A2; DK2642980T3; CY1123700T1; RS60203B1; EP2642980B8; LT2642980T; HUE049344T2; PL2642980T3; EP2642980B1; PT2642980T; US20140147497A1; SI2642980T1

Abstract

The present invention is directed to pediatric formulation of (R)-N-[-1-(1-naphthyl)-ethyl]-3-[3-(trifluoromethyl)phenyl]propan-1-amine hydrochloride (hereinafter referred to as Cinacalcet HC1) and method of administering the same.

Description

PEDIATRIC FORMULATION

CROSS-REFERENCE TO RELATED APPLICATIONS

[0001 ] This application claims the benefit of U. S. Provisional Application No.

61/416,662, filed November 23, 2010, which is hereby incorporated by reference.

FIELD OF THE INVENTION

[0002] The present invention is directed to pediatric formulation of (R)-N-[-l-(l- naphthyl)-ethyl] -3 - [3 -(trifluoromethyl)phenyl]propan- 1 -amine hydrochloride (hereinafter referred to as Cinacalcet HC1) and method of administering the same.

BACKGROUND OF THE INVENTION

[0003] Cinacalcet HC1 is an allosteric modulator of calcium-sensing receptor and is approved for the treatment of secondary hyperparathyroidism (sHPT) in ESRD (end-stage renal disease) patients. Its main function is to lower PTH and calcium in both ESRD and chronic kidney disease (CKD) patients. Currently, Cinacalcet HC1 is marketed only in tablet form. Although tablet is one of the most common drug delivery platforms, some patients, such as children, with specific disorders, may have compliance issues in taking this dosage form. An oral disintegrating tablet (ODT) dosage form was created for these patients a decade ago. This dosage form greatly enhanced the patient compliance. However, ODT technologies require specific manufacturing and packaging equipment, which is expensive. Furthermore, most ODT technologies have low production rate which further increases the manufacturing cost. In addition, ODT is soft, hygroscopic and difficult to handle. Additionally, an ODT dosage form may not work for all drug substances especially for those that show unfavorable organoleptic properties, such as bitter taste, strong odor, and numbness.

[0004] Therefore, novel formulations and delivery platform of Cinacalcet HC1 are needed to enhance the pediatric patient compliance. The present invention fulfils this and related needs.

SUMMARY OF THE INVENTION

[0005] The present invention provides a hard shell capsule containing a granular powder formulation of Cinacalcet HC1. This powder formulation can be sprinkled on and mixed with food or drinks and then administered orally to the pediatric patients. This mode of administration overcomes compliance issues in pediatric patients that are associated with administering tablet and capsule formulations. Initial studies (see Table 2) found that

Cinacalcet HC1 could not be completely sprinkled out of the capsules. Sometimes more than 50% Cinacalcet HC1 was retained in the capsule thereby resulting in severely under-dosing of the patients. Applicants have surprisingly found that an anti-adherent agent or glidant, such as silicon dioxide, when admixed in appropriate proportions with Cinacalcet HC1 containing powder formulation, can dramatically reduce the drug retention in the capsules after sprinkling, thereby making the present mode of administering Cinacalcet HC1, in therapeutic amount, to pediatric patients possible.

[0006] Accordingly, in one aspect, this invention is directed to a powder formulation, the powder comprising a therapeutically effective amount of (R)-N-[-l-(l-naphthyl)ethyl]-3- [3-(trifluoromethyl)phenyl]propan-l-amine hydrochloride admixed with at least about 2% to about 5% w/w of silicon dioxide. Preferably, the amount of silicon dioxide is between at least about 3% to about 5% w/w. More preferably, the amount of silicon dioxide is between at least about 4% to about 5% w/w. Most preferably, the amount of silicon dioxide is about 5% w/w by weight in the formulation. Preferably, the powder formulation is in granulated form.

[0007] In a second aspect, this invention is directed to a powder formulation, the powder consisting essentially of a therapeutically effective amount of (R)-N-[-l-(l-naphthyl)- ethyl]-3-[3-(trifluoromethyl)phenyl]propan-l-amine hydrochloride admixed with at least about 0.5% to about 5%, preferably 2% to about 5 % w/w of silicon dioxide. More preferably, the amount of silicon dioxide is between at least about 3% to about 5 % w/w. Most preferably, the amount of silicon dioxide is about 5% w/w by weight in the formulation. Preferably, the powder formulation is in granulated form.

[0008] In a third aspect, this invention is directed to a hard shell capsule containing a powder, the powder comprising a therapeutically effective amount of (R)-N-[-l-(l- naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-l-amine hydrochloride admixed with at least about 2% to about 5% w/w of silicon dioxide. Preferably, the amount of silicon dioxide is between at least about 3% to about 5% w/w. More preferably, the amount of silicon dioxide is between at least about 4% to about 5% w/w. Most preferably, the amount of silicon dioxide is about 5% w/w by weight in the formulation. Preferably, the powder formulation is in granulated form.

[0009] In a fourth aspect, this invention is directed to a hard shell capsule containing a powder, the powder consisting essentially of a therapeutically effective amount of (R)-N-[-l-(l- naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-l-amine hydrochloride admixed with at least about 0.5% to about 2%, preferably 2% to about 5% w/w of silicon dioxide. Preferably, the amount of silicon dioxide is between at least about 4% to about 5% w/w. More preferably, the amount of silicon dioxide is between at least about 4.5% to about 5% w/w. Most preferably, the amount of silicon dioxide is about 5% w/w by weight in the formulation.

Preferably, the powder formulation is in granulated form.

[0010] In a fifth aspect, this invention is directed to a method of treating secondary hyperparathyroidism in a pediatric patient comprising administering to the patient any of the above disclosed powder formulations. Preferably, the powder formulation is mixed with food or drinks and administered to the patient.

DETAILED DESCRIPTION

[0011 ] In the context of the foregoing and subsequent description, including the claims, the term "granulated" will be understood to refer to powder which has a particle size within the range of about 1 μηι to about 2000 μιη in diameter. Preferably, the particle size distribution in the powder formulation is as follows: the range of about 0.1% w/w to about 5% w/w has a particle size above 600 μιη, about 0.5% w/w to about 5% w/w has a particle size above 425 μιη, about 1% w/w to about 10% w/w has a particle size above 250 μιη, about 5% w/w to about 30% w/w has a particle size above 180 μιη, about 5% w/w to about 20% w/w has a particle size above 150 μιη, about 8% w/w to about 35% w/w has a particle size above 106 μιη, about 10% w/w to about 40% w/w has a particle size above 75 μιη and about 10% w/w to about 50% w/w has a particle size below 75 μιη in diameter. More preferably, the particle size distribution in the powder formulation is as follows: about 0.54% w/w has a particle size above 600 μιη, about 1.01% w/w has a particle size above 425 μιη, about 4.80% w/w has a particle size above 250 μιη, about 10.5% w/w has a particle size above 180 μιη, about 9.9% w/w has a particle size above 150 μιη, about 18.4% w/w has a particle size above 106 μιη, about 23.1% w/w has a particle size above 75 μιη, and about 31.8% w/w has a particle size below 75 μιη.

[0012] For the avoidance of any doubt when using the term % weight per weight

(% w/w) of formulation for the constituents of the formulation, those in the art understand that within a unit weight of the formulation, a certain percentage of the constituent by weight will be present, for example a 1% w/w formulation will contain within a 100 g weight of formulation, 1 g of the constituent. By way of further illustration: % w/w of component X in a Weight of X in 1 g of formulation

formulation

30% 300 mg

20% 200 mg

10% 100 mg

5% 50 mg

1% 10 mg

[0013] The powder formulation of the present invention may further comprise filler(s), binder(s), disintegrant(s), flavorant(s), sweetener(s), and other suitable excipients well known in the formulation art.

[0014] Suitable fillers, include but are not limited, to starches, lactose, mannitol,

Pearlitol(TM) SD 200, cellulose derivatives, sugar and the like. Different grades of lactose include, but are not limited, to lactose monohydrate, lactose DT (direct tableting), lactose anhydrous, Flowlac(TM) (available from Meggle products), Pharmatose(TM) (available from DMV) and others. Different grades of starches include, but are not limited to, maize starch, potato starch, rice starch, wheat starch, pregelatinized starch (commercially available as PCS PC10 from Signet Chemical Corporation) and Starch 1500, Starch 1500 LM grade (low moisture content grade) from Colorcon, fully pregelatinized starch (commercially available as National 78-1551 from Essex Grain Products) and others. Different cellulose compounds that can be used include crystalline cellulose and powdered cellulose. Examples of crystalline cellulose products include but are not limited to CEOLUS(TM) KG801, Avicel(TM) PH 101, PH102, PH301, PH302 and PH-F20, microcrystalline cellulose 1 14, and microcrystalline cellulose 112. Other useful fillers include, but are not limited to, carmellose, sugar alcohols such as mannitol, sorbitol and xylitol, calcium carbonate, magnesium carbonate, dibasic calcium phosphate, and tribasic calcium phosphate. Preferably, the filler is pregelatinized Starch 1500 and microcrystalline cellulose, Avicel pH 102. Preferably, the amount of Starch 1500 and Avicel pH 102 is between at least about 1.0% to about 99.0% w/w. More preferably, the amount of filler is between at least about 5.0% to about 80% w/w. Most preferably, the amount of Starch 1500 and Avicel pH 102 is about 10.29% and 51.39% w/w by weight, respectively in the formulation.

[0015] Suitable binders include, but are not limited to, hydroxypropylcellulose

(Klucel(TM)-LF), hydroxypropyl methylcellulose or hypromellose (Methocel(TM)), polyvinylpyrrolidone or povidone (PVP-K25, PVP-K29, PVP-K30, PVP-K90), plasdone S 630 (copovidone), powdered acacia, gelatin, guar gum, carbomer (e.g. carbopol), methylcellulose, polymethacrylates, and starch. Preferably, the binder is Povidone K29/32. Preferably, the amount of binder is between at least about 1.0 % to about 10.0 % w/w. More preferably, the amount of binder is between at least about 2.0% to about 6.0% w/w. Most preferably, the amount of binder is about 3.14% w/w by weight in the formulation.

[0016] Suitable disintegrants include, but are not limited to, carmellose calcium

(Gotoku Yakuhin Co., Ltd.), carboxy methylstarch sodium (Matsutani Kagaku Co., Ltd., Kimura Sangyo Co., Ltd., etc.), croscarmellose sodium (FMC-Asahi Chemical Industry Co., Ltd.), crospovidone, examples of commercially available crospovidone products including but not limited to crosslinked povidone, Kollidon(TM) CL [manufactured by BASF (Germany)], Polyplasdone(TM) XL, XI- 10, and INF- 10 [manufactured by ISP Inc. (USA)], and low- substituted hydroxypropylcellulose. Examples of low-substituted hydroxypropylcelluloses include but are not limited to low-substituted hydroxypropylcellulose LH11, LH21, LH31, LH22, LH32, LH20, LH30, LH32 and LH33 (all manufactured by Shin-Etsu Chemical Co., Ltd.). Other useful disintegrants include sodium starch glycolate and starch. Preferably, the disintegrant is polyplasdone XL. Preferably, the amount of disintegrant is between at least about 1.0% to about 8.0% w/w. More preferably, the amount of disintegrant is between at least about 1.5% to about 5.0% w/w. Most preferably, the amount of disintegrant is about 1.89% w/w by weight in the formulation.

[0017] Suitable anti-adherent agents or glidants, include but are not limited to, talc, silica derivatives, colloidal silicon dioxide, Syloid 244 FP and the like, and mixtures thereof. Preferably, the anti-adherent agent is Syloid 244 FP. Preferably, the amount of anti-adherent is between at least about 0.5% to about 5.0% w/w. More preferably, the amount of anti-adherent is between at least about 3.0% to about 5.0% w/w. Most preferably, the amount of anti- adherent is about 5.0% w/w by weight in the formulation.

[0018] Suitable lubricants that can be used include, but are not limited to, stearic acid and stearic acid derivatives such as magnesium stearate, calcium stearate, zinc stearate, sucrose esters of fatty acid, polyethylene glycol, talc, sodium stearyl fumarate, zinc stearate, castor oils, and waxes. Preferably, the lubricant is magnesium stearate. Preferably, the amount of lubricant is between at least about 0.10% to about 2.0% w/w. More preferably, the amount of lubricant is between at least about 0.25% to about 1.0% w/w. Most preferably, the amount of lubricant is about 0.5% w/w by weight in the formulation.

[0019] Suitable souring agents include, but are not limited to, citric acid, tartaric acid, malic acid and the like. [0020] Suitable sweeteners include, but are not limited to, artificial sweeteners such as saccharin sodium, sucralose, acesulfame K, glycyrrhizin dipotassium, aspartame, stevia, thaumatin and the like.

[0021 ] Suitable coloring agents include, but are not limited to, food dyes such as Food

Yellow No. 5, Food Red No. 2, Food Blue No. 2 and the like, as well as food lake dyes, red iron oxide and the like.

[0022] Flavors incorporated in the composition may be chosen from synthetic flavor oils and flavoring aromatics and/or natural oils, extracts from plants, leaves, flowers, fruits and so forth and combinations thereof. These may include cinnamon oil, oil of wintergreen, peppermint oils, clove oil, bay oil, anise oil, eucalyptus, thyme oil, cedar leaf oil, oil of nutmeg, oil of sage, oil of bitter almonds and cassia oil. Also useful as flavors are vanilla, citrus oil, including lemon, orange, grape, lime and grapefruit, and fruit essences, including apple, pear, peach, strawberry, raspberry, cherry, plum, pineapple, apricot and so forth. Flavors which have been found to be particularly useful include commercially available orange, grape, cherry and bubble gum flavors and mixtures thereof. The amount of flavoring may depend on a number of factors, including the organoleptic effect desired. Flavors may be present in an amount ranging from about 0.5% to about 3.0% by weight based upon the weight of the composition.

Particularly preferred flavors are the grape and cherry flavors and citrus flavors such as orange.

[0023] The present invention is useful for capsule formulations containing low doses of

Cinacalcet HC1, preferably the dose is less than 30 mg, more preferably less than 10 mg, most preferably less than 5 mg. Preferably, the powder formulation is:

EXAMPLES

EXAMPLE 1 : MANUFACTURE OF THE CINACALCET HCl PEDIATRIC CAPSULES

[0024] The present invention is directed to pediatric formulation of (R)-N-[-l-(l- naphthyl)-ethyl] -3 - [3 -(trifluoromethyl)phenyl]propan- 1 -amine hydrochloride (hereinafter referred to as Cinacalcet HCl) and method of administering the same.

FIGURE 1: FLOW DIAGRAM OF MANUFACTURING

EXAMPLE 2: FORMULATIONS AND DRUG RETENTION ASSAY STUDY

[0025] Cinacalcet HCl 1 mg pediatric capsules were prepared as in Example 1 to illustrate the present invention. The various formulations Fl, F2, F3, F4, F5, and F6 shown in Table 1 were fabricated and filled into the size two hard gelatin capsules according to the techniques known in the art to achieve 1 mg dose using Automated Micro-Filling system.

Table 1. Formulation compositions of various pediatric capsule formulations of Cinacalcet HCl

Note: Formulations F1-F4 are simple blends of formulation ingredients and F5-F6 are granular powder forms of intra-granulation and final blend of commercial Cinacalcet HCl tablet formulation

[0026] Table 2 discloses the percentage of Cinacalcet HCl that was retained in capsules after sprinkling the formulations Fl, F2, F3, F4, F5, and F6 shown in Table 1.

Table 2. % Cinacalcet HCl retained in the capsules after sprinkling of various powder formulations containing Cinacalcet HCl

Assay of filled capsu es with a target value of 100% of claim dose Assay of filled powders that are sprinkled out of capsule

c^' Assay of capsule shells after sprinkling out of filled powders

d Sum of values of b and c

[0027] The data presented in Table 2 indicates that the assay value of filled capsules was acceptable. However, it was found that different amounts of Cinacalcet HCl were retained in the capsules after sprinkling. Among the formulations Fl, F2, F3, F4, F5, and F6 evaluated, pure drug substance-containing capsules (Fl) had the least recovery, and therefore, was most retained in the capsule after sprinkling. The percentage of drug recovery increased for formulations F2 to F4 relative to Fl . In addition, it was surprisingly found that the silicon dioxide was more effective and more efficient than the diluents in enhancing recovery when taking into account the relative amount of each excipient added in the formulations.

Additionally, the recovery data from formulation F5 indicated that granulating Cinacalcet HCl with other excipients is more effective in enhancing drug recovery than simply mixing it with other formulation components (i.e., formulation F4).

[0028] Based on the drug retention results and the effect of silicon dioxide obtained in

Table 2 above, Cinacalcet HCl formulations F7, F8, F9, F10, F 12, and F13 in Table 3 were manufactured and filled into size two capsules. The formulations were sprinkled and the capsule shells were analyzed to determine how much of Cinacalcet HCl was retained after sprinkling. The results are shown in Table 4 below.

Table 3. Formulation compositions of various pediatric capsule formulations of Cinacalcet HCl

Note: Formulations F7-F9 are simple blends of formulation ingredients. Formulations F10- F 11 are binary blends of intra-granulation of commercial Cinacalcet HCl tablet and syloid 244 FP, where 98% and 95% of intra-granulation were blended with 2% and 5% Syloid 244 FP, respectively. Formulation F12 is the mixture of final blend of commercial

Cinacalcet HCl tablet formulation and Syloid 244 FP, where 2% Syloid 244 FP was added to the final blend of commercial tablet formulation.

Table 4: % Cinacalcet HCl retained in the capsules after sprinkling of various powder formulations containing Cinacalcet HCl

Assay of filled powders that are sprinkled out

c^' Assay of capsule shells after sprinkling out of filled powders

d Sum of values of b and c

[0029] The data presented in Table 4 shows that drug recovery was improved for all formulations F7, F8, F9, F 10, F12, and F13, resulting in less Cinacalcet HCl retention in the capsule shells compared to formulations F l, F2, F3, F4, F5, and F6. It should be noted that by adding 2% to 5% w/w Syloid 244 FP to formulation F2, Cinacalcet HCl retention was reduced by more than 6-fold from formulations F7 and F8; by adding 2% w/w Syloid 244 FP to formulation F4, more than 4-fold reduction of Cinacalcet HCl retention was achieved from Formulation F9. The data presented in Table 4 also indicate that addition of 2% to 5% w/w Syloid 244 FP to formulation F5 resulted in more than 18-fold reduction of Cinacalcet HCl retention from formulations F 10 and Fl l. It can be readily appreciated by a person skilled in the art that other commercial grades of silicon dioxide, such as, but not limited to, Cab-O-Sil M-5, Cab-O-Sil S-17, Cab-O-Sil M-7D, Cab-O-Sil EH-5, Aerosil OX50, Aerosil 200VV, Aerosil 130VV, Aerosil R972V, Aerosil R974V, Wacker H2000, H2015, and H2050, can be also used in the present invention. Table 5: Pediatric capsule formulation containing Cinacalcet HC1

Table 6. Cinacalcet HC1 commercial tablet formulation

[0030] The foregoing invention has been described in some detail by way of illustration and example, for purposes of clarity and understanding. It will be obvious to one of skill in the art that changes and modifications may be practiced within the scope of the appended claims. Therefore, it is to be understood that the above description is intended to be illustrative and not restrictive. The scope of the invention should, therefore, be determined not with reference to the above description, but should instead be determined with reference to the following appended claims, along with the full scope of equivalents to which such claims are entitled.

[0031 ] All patents, patent applications and publications cited in this application are hereby incorporated by reference in their entirety for all purposes to the same extent as if each individual patent, patent application or publication were so individually denoted.

Claims

CLAIMS What is claimed:

1. A formulation comprising a therapeutically effective amount of (R)-N-[- 1 -( 1 - naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]propan-l-amine hydrochloride admixed with at least about 2% w/w to about 5% w/w of silicon dioxide.

2. A powder formulation consisting essentially of a therapeutically effective amount of (R)-N-[-l-(l-naphthyl)-ethyl]-3-[3-(trifluoromethyl)phenyl]propan-l -amine hydrochloride admixed with at least about 0.5% w/w to about 5% w/w of silicon dioxide.

3. A hard shell capsule containing a powder formulation or pellet comprising a therapeutically effective amount of (R)-N-[-l-(l-naphthyl)ethyl]-3-[3-(trifluoromethyl)- phenyl]propan-l -amine hydrochloride admixed with at least about 2% w/w to about 5% w/w of silicon dioxide.

4. A hard shell capsule containing a powder formulation consisting essentially of a therapeutically effective amount of (R)-N-[-l-(l-naphthyl)ethyl]-3-[3-(trifluoromethyl)- phenyl]propan-l -amine hydrochloride admixed with at least about 0.5% w/w to about 5% w/w of silicon dioxide.

5. A method of treating secondary hyperparathyroidism in a pediatric patient comprising administering to the patient a powder formulation comprising a therapeutically effective amount of (R)-N- [- 1 -( 1 -naphthyl)ethyl] -3 -[3 -(trifluoromethyl)-phenyl]propan- 1 -amine hydrochloride admixed with at least about 2% w/w to about 5% w/w of silicon dioxide.

6. A method of treating secondary hyperparathyroidism in a pediatric patient comprising administering to the patient a powder formulation consisting essentially of a therapeutically effective amount of (R)-N-[-l-(l-naphthyl)ethyl]-3-[3-(trifluoromethyl)- phenyl]propan-l -amine hydrochloride admixed with at least about 0.5% w/w to about 5% w/w of silicon dioxide.

7. The powder formulation of any of the claims 1-4 further comprising a binder, filler, and a disintegrant.

8. The powder formulation of any of the Claims 1-4 and 7 wherein the amount of silicon dioxide is about 5% w/w.

9. A powder formulation comprising:

10. The method of Claim 5 or 6 wherein the powder formulation further comprises a binder, filler, and a dis integrant.

1 1. The method of any of the Claims 5, 6, or 10 wherein the amount of silicon dioxide in the powder formulation is about 5% w/w.

12. A method of treating secondary hyperparathyroidism in a pediatric patient comprising administering to the patient a powder formulation comprising:

13. A method of treating secondary hyperparathyroidism in a pediatric patient comprising administering to the patient a powder formulation consisting essentially of:

14. The method of any of the Claims 5, 6, and 10-13 wherein the powder formulation is mixed with food or drinks prior to administering said formulation to the patient.

15. The powder formulation of any of the Claims 1-4 and 7 wherein the amount of silicon dioxide is about 5% w/w and the formulation is in granulated form.